Morepen Laboratories Ltd Stock Price Today (NSE: MOREPENLAB)

Morepen Laboratories Ltd

MOREPENLABPharmaceuticals
51.480.80 (1.53%)
Market Open

Fundamental Score

...

Morepen Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Morepen Laboratories Ltd share price today is 51.48, down 1.53% on NSE/BSE as of 17 June 2026. Morepen Laboratories Ltd (MOREPENLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 2.38K (Cr). The 52-week high for MOREPENLAB share price is 66.40 and the 52-week low is 33.05. At a P/E ratio of 31.50x, MOREPENLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.78% and a debt-to-equity ratio of 0.13.

Morepen Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
51.48
Low
39.69
Volume
36.3L
Change
-2.43%

Morepen Laboratories Ltd share price chart: -2.43% return over the past month. 52-week high ₹66.40, 52-week low ₹33.05.

Morepen Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
46.5646.5744.9445.7945.06L (Cr)
43.7749.4943.5146.51315.93L (Cr)
42.2045.5042.2043.2485.86L (Cr)
42.2242.2242.2242.220.00 (Cr)
42.8042.8041.3842.2274.63L (Cr)
44.0045.4543.6143.9245.54L (Cr)
43.4544.0443.0043.7222.82L (Cr)
43.1944.7942.5142.9139.92L (Cr)
43.4443.7642.8242.9822.36L (Cr)
41.4942.9041.1042.5226.75L (Cr)

Morepen Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
43.7749.4943.5145.79+4.62%
41.8047.0039.6943.24+3.44%
34.5644.1834.5641.36+19.68%
41.1043.2533.0533.68-18.05%
36.6348.8434.8343.67+19.22%
41.0742.4433.5036.31-11.59%
43.6044.4038.4241.07-5.80%
47.6048.4842.4943.40-8.82%
48.1350.3847.5147.58-1.14%
46.6355.5046.6347.85+2.62%
58.5059.3445.2846.63-20.29%
62.0366.4057.0058.45-5.77%

AI Research Briefing

Powered by Gemini · 2026-04-15

Morepen's CDMO story hinges on flawless execution of its large contract and securing new deals, a risky proposition given its small-cap status and negative free cash flow.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENBreakdown. 1M: -8.64% | 3M: -10.39% | 6M: -31.88%Fair. P/E of 31.5x is in line with the industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The India Pharma 2026 conference concluded on April 15, 2026, with discussions on strengthening the pharma ecosystem.

CORE STORY (THE REAL GAME)

Why Now
  • ₹825 crore CDMO contract win
  • Q3FY26 profit increase of 3%
  • Positive sentiment from India Pharma 2026
Potential Catalysts
  • New CDMO contract wins
  • Faster-than-expected execution of existing contract
  • API price stabilization
Key Risks
  • Small-cap liquidity risk
  • Negative free cash flow
  • Execution risk on CDMO contract
Institutional Activity

FII decreased holdings by 0.1%. DII decreased holdings by 0.01%. Promoter holding steady.

Macro Context

India Pharma 2026 highlights the push for enhanced funding and infrastructure for the pharma sector.

Order Book / Expansion

₹825 crore multi-year CDMO contract from a global pharmaceutical company.

Cash Flow Quality

No. Free Cash Flow 5Y: ₹-444.19 Cr

3–6 Month Outlook

Next 3-6 months depend on CDMO execution. Watch for revenue recognition and margin impact. Key is new contract wins to sustain growth.

Primary Thesis Risk

Failure to execute the CDMO contract will lead to a significant derating.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

11.78%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.08%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

8.72%

Average operating profit margin over 5 years

Dividend Yield

0.46%

Annual dividend as % of current share price

Morepen Laboratories Ltd Valuation Check

Average

Price to Earnings (P/E)

31.50x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

35.65%

% shares held by company founders/management

Poor

FII Holding

1.62%

% shares held by foreign institutional investors

Poor

DII Holding

1.49%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-49.02%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-5.97%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

16.26%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

23.60%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

28.58%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.13x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.77x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-444.19 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Morepen Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of MOREPENLAB across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Excellent ROCE Performance (15.08%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Consistent Growth Track Record (16.26% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (23.60% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (28.58% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.13)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (7.77x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Profit Decline Concern (-49.02%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-5.97%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Negative Free Cash Flow (₹-444.19 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 3.11%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Morepen Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Morepen Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
34.5/100
51
₹2379.21
31.5
Average
11.78%
Average
15.08%
Good
0.1
Excellent
28.58%
Excellent
16.26%
Excellent
0.46%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Morepen Laboratories Ltd PE Ratio History

Historical price-to-earnings ratio for MOREPENLAB — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20252.20₹41.0718.7x
FY 20241.88₹78.1641.6x
FY 20230.77₹48.5563.1x
FY 20221.96₹37.8519.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Morepen Laboratories Ltd Quarterly Performance

Latest quarterly metrics for MOREPENLAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-5.97%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-49.02%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

16.26%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

28.58%

Compounded annual net profit growth over 5 years

Morepen Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for MOREPENLAB — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
41
▲ Price above SMA 50 — Short-term bullish
SMA 200
44
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
3720K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Morepen Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Morepen Laboratories Ltd (MOREPENLAB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Morepen Laboratories Ltd

About MOREPENLAB (Morepen Laboratories Ltd)

Morepen Laboratories Ltd is a versatile pharmaceutical organization deeply rooted in the global healthcare landscape. With a firm commitment to innovation and quality, the company ...navigates a diverse portfolio encompassing the development, production, and distribution of a wide array of pharmaceutical products. From foundational Active Pharmaceutical Ingredients (APIs) that serve as building blocks for life-saving medications, to meticulously crafted branded and generic formulations, Morepen caters to varied therapeutic needs. Furthermore, their venture into home health products empowers individuals to proactively manage their well-being, reflecting a holistic approach to healthcare. This integrated structure allows Morepen to maintain a robust presence across multiple market segments, consistently striving to meet the evolving demands of patients and healthcare professionals worldwide. The company's API segment fuels the creation of essential drugs across a spectrum of therapeutic areas. Morepen produces the foundational components needed for medications addressing conditions such as allergies, respiratory ailments, high cholesterol, hypertension, diabetes, blood clotting disorders, digestive issues, and mental health disorders. Beyond APIs, Morepen formulates and markets a range of branded and generic medications, ensuring accessibility to vital treatments. This dual approach allows the company to cater to both large pharmaceutical manufacturers and individual consumers, expanding its reach and impact on global health. By consistently upholding stringent quality standards and investing in research and development, Morepen solidifies its position as a reliable supplier of essential pharmaceutical products. Morepen Laboratories extends its reach beyond prescription drugs by offering a suite of consumer-focused home health products. Recognizing the growing importance of self-monitoring and preventative care, they provide devices that allow individuals to actively manage their health from the comfort of their homes. This includes products designed to improve air quality, along with instruments for monitoring vital signs such as blood pressure and blood glucose levels. These products empower individuals to take a proactive role in their healthcare journey, fostering a sense of control and contributing to better overall health outcomes. By diversifying into the home health sector, Morepen demonstrates its commitment to providing comprehensive healthcare solutions that address a wide range of needs.

Company Details

Symbol:MOREPENLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Sushil Suri B.Sc., F.C.A.
Chairman & MD
Mr. Sanjay Suri
Whole-Time Director
Mr. Ajay Kumar Sharma
Chief Financial Officer

MOREPENLAB Share Price: Frequently Asked Questions

What is the current share price of Morepen Laboratories Ltd?

Morepen Laboratories Ltd (MOREPENLAB) trades at ₹51.48 on NSE and BSE. Market cap ₹2.38K (Cr). Educational data only.

What is the P/E ratio of Morepen Laboratories Ltd?

Morepen Laboratories Ltd has a P/E of 31.50x vs industry average 31.77x.

What is the Bull Run score for Morepen Laboratories Ltd?

Morepen Laboratories Ltd has a Bull Run score of 34.5/100 based on 25+ financial parameters.

Does Morepen Laboratories Ltd pay dividends?

Morepen Laboratories Ltd has a dividend yield of 0.46%. Past dividends don't guarantee future payments.

What is the ROE of Morepen Laboratories Ltd?

Morepen Laboratories Ltd has ROE of 11.78%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Morepen Laboratories Ltd?

Morepen Laboratories Ltd has debt-to-equity of 0.13.

Is Morepen Laboratories Ltd a good investment?

Bull Run gives Morepen Laboratories Ltd a score of 34.5/100. This is not investment advice — consult a SEBI-registered advisor.